Stock Events

Stock Events

RenovoRx 

$0.97
20
-$0.04-3.96% Today

Statistics

Day High
1.03
Day Low
0.95
52W High
1.45
52W Low
0.7
Volume
461,672
Avg. Volume
346,900
Mkt Cap
35.55M
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

18MayExpected
Q2 2024
Q3 2024
Q1 2025
Q2 2025
Q3 2025
Q4 2025
Next
-0.12
-0.1
-0.09
-0.08
Expected EPS
-0.08
Actual EPS
N/A

Financials

-20,497.67%Profit Margin
Unprofitable
2019
2020
2021
2022
2023
2024
86,000Revenue
-17.63MNet Income

Analyst Ratings

$13.00Average Price Target
The highest estimate is 13.00.
From 1 ratings within the last 6 months. This is not an investment recommendation.
Buy
100%
Hold
0%
Sell
0%

People Also Follow

This list is based on the watchlists of people on Stock Events who follow RNXT. It's not an investment recommendation.
Alphabet
79493
GOOGL
Apple
69146
AAPL
Microsoft
64576
MSFT
Amazon
60260
AMZN

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Bioline Rx
BLRX
Mkt Cap15.55M
BioLineRx Ltd. is involved in oncology, developing treatment options for cancer, which puts it in direct competition with RenovoRx's cancer therapy solutions.
Macrogenics
MGNX
Mkt Cap104.92M
MacroGenics, Inc. focuses on discovering and developing innovative monoclonal antibody-based therapeutics for the treatment of cancer, similar to RenovoRx's approach.
Nektar Therapeutics
NKTR
Mkt Cap1.23B
Nektar Therapeutics is involved in developing drug candidates that utilize its PEGylation and polymer conjugate technology platforms, including treatments for cancer, which competes with RenovoRx's technology.
Allogene Therapeutics
ALLO
Mkt Cap275.13M
Allogene Therapeutics, Inc. is focused on the development of allogeneic CAR T therapies for cancer, offering a different approach but competing in the broader oncology treatment market with RenovoRx.

About

RenovoRx, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of solid tumors. Its lead product candidate is RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath that is in Phase III clinical trials for the locally advanced pancreatic cancer. RenovoRx, Inc. was founded in 2009 and is headquartered in Los Altos, California.
Show more...
CEO
Dr. Ramtin Agah M.D.
Employees
10
Country
US
ISIN
US75989R1077

Listings

XNAS
US
RNXT
BOATS
BOATS
RNXT.BOATS

0 Comments

Share your thoughts

FAQ

What is RenovoRx stock price today?▼
The current price of RNXT is $0.97 USD — it has decreased by -3.96% in the past 24 hours. Watch RenovoRx stock price performance more closely on the chart.
What is RenovoRx stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange RenovoRx stocks are traded under the ticker RNXT.
Is RenovoRx stock price growing?▼
RNXT stock has fallen by -11.82% compared to the previous week, the month change is a +9.85% rise, over the last year RenovoRx has showed a +1.04% increase.
What is RenovoRx market cap?▼
Today RenovoRx has the market capitalization of 35.55M
When is the next RenovoRx earnings date?▼
RenovoRx is going to release the next earnings report on May 18, 2026.
What were RenovoRx earnings last quarter?▼
RNXT earnings for the last quarter are -0.08 USD per share, whereas the estimation was -0.08 USD resulting in a +0% surprise. The estimated earnings for the next quarter are N/A USD per share.
What is RenovoRx revenue for the last year?▼
RenovoRx revenue for the last year amounts to 86,000 USD.
What is RenovoRx net income for the last year?▼
RNXT net income for the last year is -17.63M USD.
How many employees does RenovoRx have?▼
As of April 01, 2026, the company has 10 employees.
In which sector is RenovoRx located?▼
RenovoRx operates in the Health Care sector.
When did RenovoRx complete a stock split?▼
RenovoRx has not had any recent stock splits.
Where is RenovoRx headquartered?▼
RenovoRx is headquartered in Mountain View, US.